Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines

Strasbourg, France, October 5, 2016, 6:00 p.m. CET—Transgene (Euronext Paris: TNG), a company focused on designing and developing viral vector-based immunotherapies for cancer and infectious diseases, presented an original approach to improve the cytotoxic activity of oncolytic viruses at the 10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada October 1–4, 2016. This approach is based on the use of intrabodies, fragments of recombinant monoclonal antibodies designed to act intracellularly and to bypass a mechanism which prevents viral-induced cytolysis that is seen in some resistant tumor cell lines. These results open new possibilities for engineering the next generation of oncolytic viruses. The poster is available on or by clicking on this link.

Dr. Johann Foloppe, Senior Scientist, Oncolytic Virus Research, Transgene, said: “Despite recent progress in the field of oncolytic virotherapy, there is still a need to design products that could also work in cancer cells resistant to cytolysis. We identified important targets that control cytolytic activity, and have developed an original approach to block these intracellular targets. We believe this approach will allow us to generate the next generation of viral vectors with the ability to lyse cancer cells more effectively and more selectively.”

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.

Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant